早期乳腺癌内分泌治疗进展  

Progress in endocrine therapy for early breast cancer

作　　者：李珮婷 吴唯[1] 钱立元[1] 丁波泥[1] 杨萌 LI Peiting;WU Wei;QIAN Liyuan;DING Boni;YANG Meng(Department of Breast Thyroid Surgery,Third Xiangya Hospital,Central South University,Changsha 410013,China)

机构地区：[1]中南大学湘雅三医院乳甲外科

出　　处：《中南大学学报（医学版）》2019年第11期1268-1274,共7页Journal of Central South University ：Medical Science

基　　金：湖南省科学技术厅科技计划(2013SK5074)~~

摘　　要：乳腺癌是发生在乳腺腺上皮组织中的恶性肿瘤,其病因尚未完全清楚,可能与遗传及内分泌等因素相关。针对激素受体阳性的早期乳腺癌,内分泌治疗疗效显著,且服用便捷,不良反应小,因此内分泌治疗在早期乳腺癌治疗中占重要地位。但大部分患者在8~14个月后会发展为药物耐药,不得不寻求化学药物治疗或靶向治疗。目前对于内分泌治疗药物与化学药物治疗或靶向药物联合用药的效果尚存在分歧,而且绝经前后用药亦有很大差异。Breast cancer is a malignant tumor that occurs in the epithelial tissues of the breast gland.The cause of the disease is not fully understood and may be related to genetic,endocrine and other factors.For estrogen or progesterone receptor-positive early breast cancer,endocrine therapy is efficient,simple,and fewer side-effect,so endocrine therapy plays an important role in the treatment for early breast cancer.But most of them will develop drug-resistant after 8 to 14 months and have to combine with chemotherapy or molecule targeted therapy.However,there are still different ideas in the effects of endocrine therapy drugs alone or in combination with chemotherapy or molecule targeted drugs,pre-menopausally or post-menopausally.

关 键 词：早期乳腺癌 激素受体阳性 内分泌治疗 

分 类 号：R73[医药卫生—肿瘤]